56852 Federal Register / Vol. 73, No. 190 / Tuesday, September 30, 2008 / Notices 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Gender Youth and 

HIV RFA 

Date: October 23–24, 2008. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel, Washington, DC 

20005. 

Contact Person: Carla T. Walls, PhD, 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health and Human Development, NIH, 6100 

Executive Blvd., Room 5B01, Bethesda, MD 

20892, (301) 435–6898, wallsc@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: September 18, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–22895 Filed 9–29–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Prenatal 

Programming of Reproductive Health and 

Disease. 

Date: October 9, 2008. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6100 

Executive Boulevard, Room 5B01, Rockville, 

MD 20852 (Telephone Conference Call). 

Contact Person: Dennis E. Leszczynski, 

PhD, Scientific Review Administrator, 

Division of Scientific Review, National 

Institute of Child Health and Human 

Development, NIH, 6100 Executive Blvd., 

Rm. 5B01, Bethesda, MD 20892, (301) 435– 

6884, leszczyd@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: September 19, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–22896 Filed 9–29–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

License: Therapeutics Based on 

Histone Deacetylase (HDAC) Inhibitors 

for the Prevention and Treatment of 

Central Nervous System (CNS) 

Metastases of Extra-CNS Origin 

Cancers 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

Part 404.7(a)(1)(i), announces that the 

Department of Health and Human 

Services is contemplating the grant of an 

exclusive license to practice the 

inventions embodied in U.S. Provisional 

Application 60/891,856 filed February 

27, 2007 (E–084–2007/0–US–01) and 

International Application PCT/US2008/ 

055149 filed February 27, 2008 (E–084– 

2007/0–PCT–02), entitled ‘‘Use of 

Histone Deacetylase Inhibitors for the 

Treatment of Central Nervous System 

Metastases,’’ to Waypharm S.A.S. The 

patent rights in these inventions have 

been assigned to the United States of 

America. 

The prospective exclusive license 

territory may be the United States and 

Europe, and the field of use may be 

limited to therapeutics based on CNS 

metastases of extra-CNS origin cancers. 

DATES: Only written comments and/or 

license applications which are received 

by the National Institutes of Health on 

or before December 1, 2008 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent and/or patent applications, 

inquiries, comments and other materials 

relating to the contemplated exclusive 

license should be directed to: Whitney 

A. Hastings, M.S., Technology Licensing 

Specialist, Office of Technology 

Transfer, National Institutes of Health, 

6011 Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804. Telephone: 

(301) 451–7337; Facsimile: (301) 402– 

0220; E-mail: hastingw@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

invention provides a method of treating 

CNS metastasis of cancers of extra-CNS 

origin. More specifically, the method 

comprises treating CNS metastasis of 

extra-CNS origin originating in one or 

more organs such as lung, breast, liver, 

colon, and prostate with a histone 

deacetylase (HDAC) inhibitor. The 

HDAC inhibitor can be any HDAC 

inhibitor that is capable of crossing the 

blood-brain barrier (BBB) such as 

vorinostat. 

The prospective exclusive license will 

be royalty-bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless 

within sixty (60) days from the date of 

this published notice, the NIH receives 

written evidence and argument that 

establish that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: September 18, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–22893 Filed 9–29–08; 8:45 am] 

BILLING CODE 4140–01–P 


ebenthall on PROD1PC60 with NOTICES